Galantamine Hydrobromide Global Market Report 2025
상품코드:1751003
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
갈란타민브롬화수소산염 시장 규모는 향후 수 년간 급성장이 전망될 예정입니다. 예측 기간 동안 예상되는 성장은 임상 시험의 증가, 조기 진단에 대한 강조 증가, 알츠하이머병 발병률 증가, 알츠하이머병을 대상으로 한 연구 자금 및 신약 개발 노력의 확대, 연구 개발에 대한 집중 강화에 기인할 수 있습니다. 이 시기의 주요 동향으로서는 제약 기업과 연구 기관의 제휴, 치료 옵션의 진보, 진행중의 임상시험에 의한 갈란타민브롬화수소산염의 적응 확대, 맞춤형 의료의 대두, 바이오 테크놀로지와 제약 연구의 진전 등이 있습니다.
알츠하이머병의 유병률 증가는 예측 기간 중 갈란타민브롬화수소산염 시장의 확대를 촉진할 것으로 예측됩니다. 알츠하이머병은 기억 상실, 인지 기능 저하, 행동 변화를 특징으로 하는 진행성 신경 퇴행성 질환으로, 일상 활동 수행 능력을 종종 저하시킵니다. 알츠하이머병의 발병률은 세계 인구의 고령화에 의해 상승하고 있어 뇌의 변화의 축적이나 유전적 소인에 의해 노화와 함께 발병의 가능성이 현저하게 높아지기 때문입니다. 제어함으로써 아세틸콜린 농도를 높이고 신경전달 기능이 저하된 환자의 인지기능 저하를 늦추고 기억력을 높이는 것으로 알츠하이머의 증상을 관리하기 위해 사용됩니다. 미국에서 알츠하이머병 환자 수가 690만명에서 2060년까지 1,400만명 가까이 증가할 것으로 예상됩니다.
갈란타민브롬화수소산염 시장의 주요 기업은 치료 성적 개선, 부작용 경감, 환자 어드히어런스 향상을 목적으로 차세대 아세틸콜린에스테라아제 억제제(AChEI)를 개발하고 있습니다. AChEI는 부작용을 최소화하면서 생체이용률을 개선함으로써 신경퇴행성 질환의 인지 능력을 향상시키고자 합니다. Alpha Cognition Inc.는 경도에서 중등도의 알츠하이머병 치료제로서 갈란타민의 프로드러그 버전인 ALPHA-1062(Zunveyl)의 미국 FDA 승인을 취득했습니다. 표준 갈란타민과 달리, 이 약물은 소장에서 불활성 물질로 흡수되어 위장 시스템에서 아세틸콜린에스터라아제와의 초기 상호작용을 피합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 갈란타민브롬화수소산염의 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 갈란타민브롬화수소산염 시장 : 성장률 분석
세계의 갈란타민브롬화수소산염 시장 실적: 규모와 성장, 2019-2024년
세계의 갈란타민브롬화수소산염 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 갈란타민브롬화수소산염 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 갈란타민브롬화수소산염 시장 : 제품 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
정제
캡슐
경구용액
세계의 갈란타민브롬화수소산염 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
알츠하이머병 치료
인지기능 향상
기타
세계의 갈란타민브롬화수소산염 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
병원
연구기관
재택 케어 설정
장기 케어 시설
세계의 갈란타민브롬화수소산염 시장 : 정제의 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
즉방성정
서방형정
세계의 갈란타민브롬화수소산염 시장 : 캡슐의 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
하드 젤라틴 캡슐
소프트젤라틴 캡슐
세계의 갈란타민브롬화수소산염 시장 : 경구용액의 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
즉시 사용할 수있는 경구 용액
농축 경구 용액
제7장 지역별/국가별 분석
세계의 갈란타민브롬화수소산염 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 갈란타민브롬화수소산염 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
갈란타민브롬화수소산염 시장 : 경쟁 구도
갈란타민브롬화수소산염 시장 : 기업 프로파일
Teva Pharmaceutical Industries Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sandoz International GmbH : 개요, 제품 및 서비스, 전략 및 재무 분석
Ajinomoto Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sun Pharmaceutical Industries Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Aurobindo Pharma Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Dr. Reddy's Laboratories Ltd.
Jubilant Pharmova Limited
Cohance Lifesciences Limited
Indena SpA
ScinoPharm Taiwan Ltd.
Estechpharma Co. Ltd.
Nortec Quimica SA
Metrochem API Private Limited
Sanochemia Pharmazeutika AG
Pellets Pharma Limited
Midas Pharma GmbH
Jubilant Generics
Capital Farma
Wuhan Shiji Pharmaceutical Co. Ltd.
Credo Life Sciences Pvt. Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
갈란타민브롬화수소산염 시장 2029 : 새로운 기회를 제공하는 국가
갈란타민브롬화수소산염 시장 2029 : 새로운 기회를 제공하는 부문
갈란타민브롬화수소산염 시장 2029 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Galantamine hydrobromide is a pharmaceutical compound used to treat mild to moderate Alzheimer's disease and other memory-related conditions. As an acetylcholinesterase inhibitor, it works by increasing acetylcholine levels in the brain, which improves nerve signal transmission and cognitive function. Galantamine hydrobromide helps slow cognitive decline and enhances memory, attention, and overall mental function in patients with neurodegenerative disorders.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main galantamine hydrobromide products include tablets, capsules, and oral solutions. Tablets are solid forms of medicine taken orally, where they dissolve in the digestive system to release the active ingredients. Galantamine hydrobromide is used for treating Alzheimer's disease, enhancing cognitive function, and other purposes by various end-users, including hospitals, research institutions, homecare settings, and long-term care facilities.
The galantamine hydrobromide market research report is one of a series of new reports from The Business Research Company that provides galantamine hydrobromide market statistics, including galantamine hydrobromide industry global market size, regional shares, competitors with a galantamine hydrobromide market share, detailed galantamine hydrobromide market segments, market trends and opportunities, and any further data you may need to thrive in the galantamine hydrobromide industry. This galantamine hydrobromide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The galantamine hydrobromide market size has grown rapidly in recent years. It will grow from $0.67 billion in 2024 to $0.74 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth observed during the historic period can be attributed to rising investments, a growing elderly population, an increasing diagnosis rate, heightened awareness of neurodegenerative illnesses, and a rise in life expectancy.
The galantamine hydrobromide market size is expected to see rapid growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth projected during the forecast period can be attributed to an increase in clinical trials, a growing emphasis on early diagnosis, a rising incidence of Alzheimer's disease, expanded research funding and drug development efforts targeting Alzheimer's, and a strengthened focus on research and development. Key trends during this period include collaborations between pharmaceutical companies and research institutions, advancements in treatment options, the expansion of indications for galantamine hydrobromide through ongoing clinical trials, the rise of personalized medicine, and progress in biotechnology and pharmaceutical research.
The growing prevalence of Alzheimer's disease is expected to drive the expansion of the galantamine hydrobromide market over the forecast period. Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes, often impairing the ability to carry out everyday activities. The incidence of Alzheimer's is rising due to the aging global population, as the likelihood of developing the disease increases significantly with age due to accumulated brain changes and genetic predisposition. Galantamine hydrobromide is used to manage Alzheimer's symptoms by increasing acetylcholine levels through inhibition of its breakdown, thereby helping to slow cognitive decline and enhance memory in patients with reduced neurotransmitter function. For instance, in August 2024, the Centers for Disease Control and Prevention (CDC) reported that the number of individuals living with Alzheimer's in the U.S. is expected to rise from 6.9 million to nearly 14 million by 2060. Therefore, the increasing prevalence of Alzheimer's disease is driving the growth of the galantamine hydrobromide market.
Leading companies in the galantamine hydrobromide market are developing next-generation acetylcholinesterase inhibitors (AChEIs) to improve treatment outcomes, reduce side effects, and promote better patient adherence. These advanced AChEIs aim to enhance cognitive performance in neurodegenerative conditions by improving bioavailability while minimizing adverse effects. For example, in July 2024, Alpha Cognition Inc., a Canada-based biopharmaceutical company, received U.S. FDA approval for ALPHA-1062 (Zunveyl), a prodrug version of galantamine for mild to moderate Alzheimer's disease. ALPHA-1062 features improved safety and bioavailability compared to traditional formulations. Unlike standard galantamine, it is absorbed in the small intestine as an inert substance, avoiding early interaction with acetylcholinesterase in the gastrointestinal system. The addition of a benzyl ester helps reduce local neuronal overstimulation, lessens gastrointestinal side effects, and enhances bioavailability. Once metabolized in the liver, ALPHA-1062 becomes active and delivers galantamine efficiently to the brain through the bloodstream.
In April 2024, Essential Pharma Group Limited, a UK-based specialty pharmaceutical company, acquired the oral capsule formulation of Reminyl (galantamine hydrobromide) from Janssen Pharmaceutica NV for an undisclosed amount. This acquisition ensures the continued availability of and access to galantamine hydrobromide treatment for Alzheimer's patients. Janssen Pharmaceutica, a Belgium-based pharmaceutical company, is known for developing therapies across several fields including neurology, infectious diseases, immunology, oncology, and cardiology.
Major players in the galantamine hydrobromide market are Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ajinomoto Co. Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Jubilant Pharmova Limited, Cohance Lifesciences Limited, Indena S.p.A., ScinoPharm Taiwan Ltd., Estechpharma Co. Ltd., Nortec Quimica S.A., Metrochem API Private Limited, Sanochemia Pharmazeutika AG, Pellets Pharma Limited, Midas Pharma GmbH, Jubilant Generics, Capital Farma, Wuhan Shiji Pharmaceutical Co. Ltd., Credo Life Sciences Pvt. Ltd.
North America was the largest region in the galantamine hydrobromide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in galantamine hydrobromide report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the galantamine hydrobromide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The galantamine hydrobromide market consists of sales of extended-release capsules, injectable solutions, transdermal patches, sublingual drops, and powder for compounding. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Galantamine Hydrobromide Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on galantamine hydrobromide market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for galantamine hydrobromide ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The galantamine hydrobromide market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Tablet; Capsule; Oral Solution
2) By Application: Alzheimer's Disease Treatment; Cognitive Enhancements; Other Applications
3) By End-User: Hospitals; Research Institutions; Homecare Settings; Long-term Care Facilities
Subsegments:
1) By Tablet: Immediate-Release Tablets; Extended-Release Tablets
2) By Capsule: Hard Gelatin Capsules; Soft Gelatin Capsules
3) By Oral Solution: Ready-to-Use Oral Solution; Concentrated Oral Solution
Companies Mentioned: Teva Pharmaceutical Industries Ltd.; Sandoz International GmbH; Ajinomoto Co. Inc.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Limited
3. Galantamine Hydrobromide Market Trends And Strategies
4. Galantamine Hydrobromide Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Galantamine Hydrobromide Growth Analysis And Strategic Analysis Framework
5.1. Global Galantamine Hydrobromide PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Galantamine Hydrobromide Market Growth Rate Analysis
5.4. Global Galantamine Hydrobromide Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Galantamine Hydrobromide Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Galantamine Hydrobromide Total Addressable Market (TAM)
6. Galantamine Hydrobromide Market Segmentation
6.1. Global Galantamine Hydrobromide Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tablet
Capsule
Oral Solution
6.2. Global Galantamine Hydrobromide Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alzheimer's Disease Treatment
Cognitive Enhancements
Other Applications
6.3. Global Galantamine Hydrobromide Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Research Institutions
Homecare Settings
Long-term Care Facilities
6.4. Global Galantamine Hydrobromide Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immediate-Release Tablets
Extended-Release Tablets
6.5. Global Galantamine Hydrobromide Market, Sub-Segmentation Of Capsule, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hard Gelatin Capsules
Soft Gelatin Capsules
6.6. Global Galantamine Hydrobromide Market, Sub-Segmentation Of Oral Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ready-to-Use Oral Solution
Concentrated Oral Solution
7. Galantamine Hydrobromide Market Regional And Country Analysis
7.1. Global Galantamine Hydrobromide Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Galantamine Hydrobromide Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
